Andrew Combs - Net Worth and Insider Trading
Andrew Combs Net Worth
The estimated net worth of Andrew Combs is at least $689,737 dollars as of 2024-09-20. Andrew Combs is the EVP, Head of Chemistry of Prelude Therapeutics Inc and owns about 268,380 shares of Prelude Therapeutics Inc (PRLD) stock worth over $689,737. Details can be seen in Andrew Combs's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Andrew Combs has not made any transactions after 2021-12-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Andrew Combs
Andrew Combs Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Andrew Combs owns 1 companies in total, including Prelude Therapeutics Inc (PRLD) .
Click here to see the complete history of Andrew Combs’s form 4 insider trades.
Insider Ownership Summary of Andrew Combs
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2021-12-14 | EVP & Head of Chemistry |
Andrew Combs Latest Holdings Summary
Andrew Combs currently owns a total of 1 stock. Andrew Combs owns 268,380 shares of Prelude Therapeutics Inc (PRLD) as of December 14, 2021, with a value of $689,737.
Latest Holdings of Andrew Combs
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2021-12-14 | 268,380 | 2.57 | 689,737 |
Holding Weightings of Andrew Combs
Andrew Combs Form 4 Trading Tracker
According to the SEC Form 4 filings, Andrew Combs has made a total of 2 transactions in Prelude Therapeutics Inc (PRLD) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Prelude Therapeutics Inc is the acquisition of 8,000 shares on December 14, 2021, which cost Andrew Combs around $94,880.
Insider Trading History of Andrew Combs
- 1
Andrew Combs Trading Performance
GuruFocus tracks the stock performance after each of Andrew Combs's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andrew Combs is 78.47%. GuruFocus also compares Andrew Combs's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andrew Combs within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Andrew Combs's insider trading performs compared to the benchmark.
Performance of Andrew Combs
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.34 | | | | | |
| Relative Return to S&P 500(%) | 0.41 | | | | | |
Andrew Combs Ownership Network
Andrew Combs Owned Company Details
What does Prelude Therapeutics Inc do?
Who are the key executives at Prelude Therapeutics Inc?
Andrew Combs is the EVP & Head of Chemistry of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include director & President & CEO Krishna Vaddi , Chief Legal Counsel & Corp Sec. Bryant David Lim , and Chief Financial Officer Laurent Chardonnet .
Prelude Therapeutics Inc (PRLD) Insider Trades Summary
Over the past 18 months, Andrew Combs made no insider transaction in Prelude Therapeutics Inc (PRLD). Other recent insider transactions involving Prelude Therapeutics Inc (PRLD) include a net purchase of 13,756 shares made by Krishna Vaddi , a net purchase of 869,565 shares made by Orbimed Advisors Llc , and a net purchase of 869,565 shares made by David P Bonita .
In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 13,280 shares of Prelude Therapeutics Inc (PRLD) were sold and 1,760,286 shares were bought by its insiders, resulting in a net purchase of 1,747,006 shares.
Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prelude Therapeutics Inc Insider Transactions
Andrew Combs Mailing Address
Above is the net worth, insider trading, and ownership report for Andrew Combs. You might contact Andrew Combs via mailing address: C/o Prelude Therapeutics Incorporated, 200 Powder Mill Road, Wilmington De 19803.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
